



## Global Product Development

16 August 2021

Marion Gruber, Ph.D.  
Director  
Office of Vaccines Research and Review  
Food and Drug Administration  
Center for Biologics Evaluation and Research  
Document Control Center  
10903 New Hampshire Avenue  
WO71, G112  
Silver Spring, MD 20993-0002

THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR PFIZER INC OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.

**Re: BLA 125742**

**COVID-19 mRNA Vaccine (BNT162/PF-07302048)**

**Response to FDA 13 August 2021 Third Round of Comments on the Draft Package Insert for COMIRNATY**

Dear Dr. Gruber,

Reference is made to the Biologics License Application (BLA) submitted 19 May 2021 for the COVID-19 mRNA Vaccine (BNT162/PF-07302048) developed by BioNTech and Pfizer under BB-IND 19736 for the prevention of COVID-19 caused by SARS-CoV-2 in individuals  $\geq 16$  years of age.

The present submission provides responses and updates to the Agency's 13 August 2021 third round of requested changes on the draft package insert for COMIRNATY. The updated draft package insert is provided in Module 1.14.1:

- Track change ([PDF](#) and [Word](#))
- Annotated ([PDF](#) and [Word](#))
- Clean copy ([PDF](#) and [Word](#))

Should you have any questions regarding this submission, or require additional information, please contact me via phone at 215-280-5503; via facsimile at 845-474-3500; or via e-mail at [elisa.harkinstull@pfizer.com](mailto:elisa.harkinstull@pfizer.com).

Sincerely,

Elisa Harkins  
Global Regulatory Lead  
Global Regulatory Affairs – Vaccines

CC: Ramachandra S. Naik, Ph.D.